Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt
New vaccine introductions (NVIs) raise issues of value for money (VfM) for self-financing middle-income countries like Egypt. We evaluate a pediatric pneumococcal conjugate vaccine (PCV) NVI in Egypt from health payer and societal perspectives, using cost-utility and cost-benefit analysis (CUA, CBA)...
Saved in:
Main Authors: | JP Sevilla (Author), Daria Burnes (Author), Rehab Zakaria El Saie (Author), Hammam Haridy (Author), Matt Wasserman (Author), Sarah Pugh (Author), Johnna Perdrizet (Author), David Bloom (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021) -
Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
by: Derek Lytle, et al.
Published: (2023) -
An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024) -
Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
by: J. P. Sevilla, et al.
Published: (2020) -
Cost-utility and cost-benefit analyses of school-based obesity prevention program
by: Haiquan Xu, et al.
Published: (2020)